Skip to main content

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Rafael Simó Canonge

Institutions of which they are part

Head of group
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

ADMINISTRACION TOPICA DE AGONISTAS DEL RECEPTOR DE GLP-1: UNA NUEVA ESTRATEGIA PARA EL TRATAMIENTO DE LA RETINOPATIA DIABETICA

IP: Rafael Simó Canonge
Collaborators: Hugo Ramos Abellan, Miriam Izquierdo Sans
Funding agency: Ministerio Economía, Industria y Competitividad
Funding: 96843.15
Reference: BES-2017-081690
Duration: 01/07/2018 - 30/11/2022

Models of Patients Engagement for Alzheimer’s Disease (MOPEAD)

IP: Rafael Simó Canonge
Collaborators: Laia Perez Lasarte
Funding agency: Instituto de Salud Carlos III
Funding: 30000
Reference: INT18/00026
Duration: 01/01/2019 - 31/12/2019

MOPEAD

IP: Rafael Simó Canonge
Collaborators: Angel Michael Ortiz Zúñiga, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 47268
Reference: 2018/VHIR/ORTIZ
Duration: 01/07/2019 - 30/06/2022

Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of dementia

IP: Rafael Simó Canonge
Collaborators: Marina Jimenez Iglesias, Cristina Hernández Pascual, Retinal and cognitive dysfunction in type 2 diabetes: unraveling the common pathways and identification of patients at risk of d, Patricia Bogdanov Baruj, Andreea Ciudin Mihai, Ferran Casals Riera, Itziar Busquets Saez, Maddalen Zufiaurre Seijo, Enrique Franky Vargas, José Raul Herance Camacho, Ingrid Balcells Ortega, Marco Inzitari
Funding agency: EUROPEAN COMMISSION
Funding: 974782.7
Reference: RECOGNISED_H2020SC1BHC2019
Duration: 01/01/2020 - 31/12/2024

Related news

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Dr. Maria Llorián-Salvador, from the Diabetes and Metabolism Research Group at VHIR, is leading this project to identify new therapies for this inherited disease that causes progressive vision loss.

Related professionals

Santos Ortega, Alba

Santos Ortega, Alba

Predoctoral researcher
Cardiovascular Diseases
Read more
López Gutierrez, Pere

López Gutierrez, Pere

Research technician
Cardiovascular Diseases
Read more
Pascual González, Gabriel

Pascual González, Gabriel

Cardiovascular Diseases
Read more
Falcó Roget, Anna

Falcó Roget, Anna

Research technician
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.